Fate Therapeutics, Inc.

NASDAQ:FATE

Biotechnology

Healthcare
$1.05 -0.00%

-$0.00 today

Market cap
$122.39M
Beta
2.52
P/E (TTM)
-1.8
EPS (TTM)
-$1.08
52W Low $0.91High $2.88

Volume 1.87M

Average 2.92M

FATE Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Fate Therapeutics, Inc.NASDAQ: FATE

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue declines year over year

Q1 FY2026 cost of revenue of $2.92M fell 90.0% year over year, behind the -62.0% change in trailing-twelve-month cost of revenue. Over 3 fiscal years it compounded at -2.1% a year.

Context

  • Cost of revenue amounted to 194.1% of revenue in FY2025, down 675.5 pp from a year earlier.
  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -90.0% toward the trailing-twelve-month pace of -62.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.92M— QoQ
Last fiscal yearDec 2025
$12.9M-89.1% YoY
LTMMar 2026
$32.58M-62.0% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-90.0%——
1 year-89.1%——
3-year CAGR-2.1%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
12.9M USD
Year-over-year change
-89.1%
4-year CAGR
+21.9%

Cost of Revenue vs competitors

How FATE compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -62.0% is the 4th highest of 8, against a peer median of -64.0%.
  • Cost of revenue amounts to 515.8% of revenue for FATE, versus a peer median of 81.8%.
FATE Competitors
Cost of Revenue for FATE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FATEFate Therapeutics, Inc.LTM Mar 2026$32.58M USD-62.0%-2.1%515.8%
ALECAlector, Inc.LTM Mar 2026$29.7M USD-64.0%—161.2%
MOLNMolecular Partners AGLTM Mar 2026CHF 2.61M CHF-92.3%-62.9%—
NKTXNkarta, Inc.LTM Mar 2026$2.34M USD———
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$2.24M USD+39.7%——
PEPGPepGen Inc.LTM Mar 2026$1.72M USD+351.6%——
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$391K USD——2.3%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$149K USD-99.1%——
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$46K USD+4.5%——
VORVor Biopharma Inc.LTM Mar 2026$28K USD-98.4%——
Peer median (excluding FATE) —-64.0%-62.9%81.8%

Competitors are the stored peer set for FATE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue55.85M96.3M63.53M13.63M6.65M
Cost of Revenue5.85M13.76M157.19M118.53M12.9M
Gross Profit50M82.54M(93.65M)(104.9M)(6.26M)
Gross Margin89.5%85.7%-147.4%-769.6%-94.1%
Research & Development215.52M320.45M172.6M135M107.83M
Selling, General & Admin57.32M84.23M96.86M90.64M46.52M
Operating Expenses266.99M390.93M96.86M105.38M141.45M
Depreciation & Amortization5.85M13.76M18.28M18.96M9.3M
EBITDA(206.3M)(267.96M)(142.65M)(176.58M)(127.02M)
EBITDA Margin-369.4%-278.3%-224.5%-1295.4%-1911.2%
Operating Income(216.99M)(308.39M)(190.51M)(210.28M)(147.7M)
Operating Margin-388.6%-320.2%-299.9%-1542.6%-2222.4%
Interest Income1.31M5.84M17.19M17.29M11.05M
Interest Expense00000
Other Income / Expenses4.84M26.67M29.58M24.01M11.39M
Income Before Tax(212.15M)(281.72M)(160.93M)(186.26M)(136.32M)
Pre-Tax Margin-379.9%-292.5%-253.3%-1366.5%-2051.1%
Income Tax Expense00000
Net Income(212.15M)(281.72M)(160.93M)(186.26M)(136.32M)
Net Margin-379.9%-292.5%-253.3%-1366.5%-2051.1%
EPS (Basic)(2.24)(2.91)(1.64)(1.64)(1.15)
EPS (Diluted)(2.24)(2.91)(1.64)(1.64)(1.15)
Weighted Avg Shares94.75M96.83M98.41M113.69M118.79M
Weighted Avg Shares (Diluted)94.75M96.83M98.41M113.69M118.79M

Fate Therapeutics, Inc.

NASDAQ:FATE

Intrinsic Alpha fair value

Locked

Current Price

$1.05

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.